Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Fish oil infusions tested to tame transplant complication

NCT ID NCT07162688

Disease control Sponsor: Fujian Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether daily intravenous omega-3 fatty acids (fish oil) can reduce the risk and severity of acute graft-versus-host disease (aGVHD) in 30 adults receiving a stem cell transplant. Participants get omega-3 infusions from before transplant until about 35 days after. The main goal is to see if fewer people develop aGVHD within 100 days.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Omega-3 fatty acids (fish oil) given intravenously
What this could lead to
If it works, this could offer a simple, safe way to lower the risk of a serious complication after stem cell transplant.
What could go wrong
This is a small, early-phase trial with only 30 people, so results may not apply widely. Omega-3 may not reduce GVHD enough to change standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) 2. Age 18 to 65 years (inclusive) 3. Male or female 4. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 3 5. Expected survival of at least 100 days 6. Willingness to participate and provide written informed consent Exclusion Criteria: 1. History of solid organ transplantation 2. Serum triglycerides ≥ 7.9 mmol/L 3. Uncontrolled diabetes 4. Severe dyslipidemia (e.g., LDL-C ≥ 4.9 mmol/L) 5. Contraindications to parenteral nutrition (e.g., severe electrolyte imbalance, acidosis) 6. Severe hepatic impairment (AST/ALT \> 3× ULN) 7. Creatinine clearance \< 15 mL/min 8. Known allergy to Omega-3, fish, or egg protein 9. Significant psychiatric illness or substance abuse interfering with study compliance 10. Participation in another clinical trial or receipt of other experimental treatments during the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute-graft-versus-host disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute graft versus host disease graft versus host disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Graft-versus-host disease(GVHD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The First Affiliated Hospital of Fujian Medical University

    Fuzhou, Fujian, 353000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.